เอกสารอ้างอิง
1. MIMs Thailand. Omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole. [database on the internet]. 2019 [cited 2020 Dec 18]. Available from: https://www.mims.com
2. Strand DS, Kim D, Peura DA. 25 Years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017 Jan 15;11(1):27-37. doi: 10.5009/gnl15502.
3. Vegesna V et al. Assessing the bioequivalence of over-the-counter esomeprazole banded capsules and multiple-unit pellet system tablets. Int J Clin Pharmacol Ther. 2018 Feb;56(2):92-99.
4. Talpes S et al. Esomeprazole MUPS 40 mg tablets and esomeprazole MUPS 40 mg tablets encapsulated in hard gelatine are bioequivalent. Int J Clin Pharmacol Ther. 2005 Jan;43(1):51-6.
5. Reddy S et al. MUPS (Multiple Unit Pellet System) Tablets – A Brief Review. Journal of pharmaceutical and biomedical sciences. 2011;12(02):1-4
6. Horn JR, Howden CW. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations. Aliment Pharmacol Ther. 2005 Dec;22 Suppl 3:20-4.
7. Baldi F, Malfertheiner P. Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor. Digestion. 2003;67(1-2):1-5.
8. Howden CW. Update on dual delayed-Release PPI formulations. Gastroenterol Hepatol (N Y). 2010 Jul;6(7):417-9.
9. Kirchheiner J et al. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009 Jan;65(1):19-31.
10. Graham DY, Tansel A. Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency. Clin Gastroenterol Hepatol. 2018 Jun;16(6):800-808.e7.
11. Li MJ et al. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis. Medicine (Baltimore). 2017 Sep;96(39):e8120.
12. Li XQ et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7.
13. Frelinger AL et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012 Apr 3;59(14):1304-11.
14. Choi YJ et al. Pantoprazole does not reduce the antiplatelet effect of clopidogrel: a randomized controlled trial in korea. Gut Liver. 2017 Jul 15;11(4):504-511.
15. Majithia R, Johnson DA. Are proton pump inhibitors safe during pregnancy and lactation? Evidence to date. Drugs. 2012 Jan 22;72(2):171-9.